Bloodwork Cadence: When and How Often to Test

One of the quiet ways online TRT clinics make money is by ordering more bloodwork than you actually need. The clinic framing is usually that frequent testing is the responsible thing to do. In the early months of a new protocol, that is true. After the first year on a stable dose, it is mostly not.

This article is the short version of how to think about bloodwork cadence on TRT. When to test, what to test at each checkpoint, and how to read the trends across a year. For the marker-level deep dive, see The 5 Blood Markers Every Man Over 35 Should Track. For how to read a panel, see How to Read Your Own Bloodwork. For the deeper reference, see the bloodwork wiki.

The logic of cadence

Bloodwork on TRT has two purposes. The first is to confirm that the protocol is producing the intended effect on your hormonal state. The second is to catch any drift or unexpected changes in markers that require intervention.

Both purposes are well-served by dense early testing when the response curve is unknown and you are adjusting the protocol. Both purposes are poorly served by continuing that density once the protocol is stable, the response is understood, and no markers are drifting.

The pattern that makes sense for most men:

• Dense testing in the first year. You are figuring out how your body responds to the protocol, making adjustments, and establishing a baseline for what “stable on TRT” looks like for you.
• Sparse testing after the first year. Once the protocol is stable and the numbers are holding, the value of additional testing drops quickly. Twice a year is enough for most stable patients.
• Trigger-based extra testing. Outside the scheduled cadence, test any time something changes (new symptoms, protocol change, life change) or if a previous result was unexpected.

The extra testing that clinics push beyond this cadence is mostly a billing decision, not a medical one.

The first year schedule

The cadence that works for most men in year one:

Baseline (before starting TRT). Full male hormone panel, metabolic panel, thyroid, inflammatory markers, full lipid panel, hematocrit and hemoglobin, ferritin, vitamin D. This is the widest panel you will order all year. Everything else gets compared against this.

6 weeks after starting. Short follow-up panel. Total T, free T (or SHBG so you can calculate it), sensitive estradiol, hematocrit. The point is to see where the protocol landed on the testosterone and estradiol side and make sure hematocrit is not drifting. You do not need the full panel at 6 weeks. You need the response markers.

12 weeks after starting. Same short panel as 6 weeks, plus a lipid panel if you are on a dose or delivery method that could affect lipids (oral forms in particular). By 12 weeks you have enough information to know whether the protocol is working and whether any small adjustments are needed.

24 weeks after starting. Medium panel. The short follow-up markers plus SHBG, LH, FSH (useful for confirming appropriate HPG axis suppression on TRT, which is expected), and an updated metabolic panel. This is where you are starting to see whether the response has held through the first six months.

52 weeks after starting. Full panel. Same scope as the baseline plus anything that has come up during the year. This is the annual full re-check and should look similar in scope to the initial baseline so you can compare the same markers.

That is five panels in year one: baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks. Any protocol adjustments along the way should be followed by a confirmatory check 6 weeks after the adjustment, which may add one or two extra panels.

After year one

Once the protocol is stable and the first-year data looks good, the cadence relaxes.

Twice a year, ongoing. Full panel at one, medium panel at the other. Six months apart. This is enough for most stable patients to catch drift early, monitor hematocrit, and confirm the protocol is still doing what it is supposed to.

Any time something changes. New symptoms, protocol change, new medication, major life stressor, significant body composition change. Any of these is a reason to test sooner.

Any time a previous result was unexpected. If hematocrit ticks up to 51, you retest in 6 weeks rather than waiting the full 6 months. If SHBG moves 20 percent from one check to the next, you retest sooner to confirm it was a real shift rather than day-to-day variation.

Some clinics continue quarterly testing indefinitely. For a man on a stable protocol with unremarkable labs, that cadence is usually more about revenue than about medical necessity. Ask your provider what the specific decision would be that requires quarterly rather than semi-annual data. If the answer is vague, the answer is probably that the clinic prefers quarterly for billing reasons.

What to draw and when

A few principles that make your bloodwork data actually useful rather than noisy.

Draw before 10 AM. Testosterone has a diurnal rhythm, highest in the morning and dropping through the day. Consistent morning draws make results comparable across months.

Draw at a consistent point in the injection cycle. If you inject Sunday and Wednesday, drawing blood on Tuesday morning (mid-cycle) gives you the most stable number across time. Drawing sometimes at trough (Sunday morning) and sometimes at peak (Monday morning) produces data that looks like it is changing when the protocol is actually stable. Pick a point and stick to it.

Fasting for metabolic panels. If you are getting lipids, glucose, or insulin, fast 10-12 hours before the draw. Not required for the hormone panel alone but required for the metabolic markers to be interpretable.

Hold off on heavy workouts for 24 hours. Intense training elevates CK, can affect hematocrit, and shifts some markers in ways that do not reflect your steady state.

Same lab, same assay. If you can, use the same lab (LabCorp or Quest) for all your draws. Different labs use different assays and different reference ranges, and comparing results across labs introduces noise.

Sensitive estradiol, not standard. This matters enough that it deserves its own article. For the argument, see Dialing In Estradiol. The short version: men should use the sensitive LC-MS/MS assay because the standard assay is not reliable at male concentrations.

Tracking the trend

Single lab results are not the unit of analysis. The unit of analysis is the trend across time. A spreadsheet is enough. Columns for date, total T, free T, SHBG, sensitive estradiol, hematocrit, and any other marker you care about tracking. One row per draw.

What you are looking for:

• Stable markers at consistent values. This is the “nothing to do” signal and the most common finding on a stable protocol.
• Gradual drift. A slow change in one marker across multiple draws. Hematocrit creeping up from 46 to 48 to 50 over three checks is a real trend. A one-time reading of 48 is not.
• Sudden shifts. A single outlier result, especially in a marker that has been stable, is often noise rather than signal. Confirm with a repeat draw before adjusting the protocol.
• Divergences between markers that usually track together. SHBG and free T usually move in predictable ways together. If they stop, that is a signal to look more closely.

The value of keeping your own spreadsheet is that your clinic will not always notice trends that span across more draws than a single visit covers. A provider looking at your current result plus the last one is missing context that the full six-result trend across 18 months would make obvious. You are the one in position to notice that kind of pattern. Keep the data.

Where to get the labs

You do not have to route all your bloodwork through your clinic. Direct-to-consumer lab ordering through Ulta Lab Tests, DiscountedLabs, Marek Health, or similar services works for most of the markers you care about. You order online, walk into a LabCorp or Quest draw station, get drawn, and results land in your patient portal within a few days. For a standard follow-up panel, DTC typically costs $80-200 depending on the markers. Your clinic-routed labs typically cost $150-400 for the same scope.

The DTC path has one caveat: if your clinic requires its own labs for protocol adjustments, you may end up paying for both. Ask your provider whether they will accept DTC labs for interim checks. Many DPC physicians will. Many online clinics will not. Find out before you commit to a path.

For a stable patient on a stable protocol, running the semi-annual panels through DTC and only doing clinic-routed labs for the annual full panel is a reasonable balance between cost and convenience. The trend you care about is the one in your spreadsheet, not the one in the clinic’s patient portal.

The honest framing

Bloodwork is important. Bloodwork cadence is a real clinical decision. The cadence most online TRT clinics recommend in year two and beyond is not the cadence most stable patients actually need, and the gap between those two is the clinic’s billing margin.

Be dense at the start when you need the data. Be sparse when you have the data and nothing is changing. Test whenever something changes. Keep your own trend spreadsheet. Use the sensitive estradiol assay. Draw at consistent times. Compare across time, not to a single reference range.

That is enough to catch the things that matter without paying for tests that do not.